By leveraging Viz HCM, which is incorporated into the Viz.ai platform, physicians can identify more individuals with suspected HCM, tapping AI. Credit: comzeal images / Shutterstock.com.

The US Food and Drug Administration (FDA) has granted De Novo approval for Viz.ai’s hypertrophic cardiomyopathy (HCM) artificial intelligence (AI) detection algorithm, Viz HCM module.

Bristol Myers Squibb provided financial backing for the algorithm’s implementation through a multi-year agreement announced in March this year.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

By leveraging Viz HCM, which is incorporated into the Viz.ai platform, physicians can identify more individuals with suspected HCM by tapping AI and triaging them for diagnosis and further analysis.

To detect suspected HCM cases and notify cardiologists and care teams through the Viz mobile application, the Viz HCM module automatically reviews routine electrocardiograms (ECGs) from across a health system.

Later, medical professionals can examine the patient’s ECG, arrange a follow-up echocardiogram for diagnosis and utilise the Viz Echo Viewer to assess images and obtain echocardiogram reports.

The HCM module stands as one of 12 FDA-approved AI algorithms on the enterprise-wide, clinically validated Viz.ai Platform, according to the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company has also claimed that this platform has demonstrated its capacity to enhance treatment accessibility and boost patient outcomes across over 1,400 hospitals in the US and Europe.

Viz.ai CEO and founder Chris Mansi said: “The ongoing investment of innovative capabilities on our platform is why it continues to be the first choice of leading healthcare systems.

“With our AI-powered Viz HCM module, we look forward to realising its promise in expediting the detection and care of patients with this common, inherited heart disease.”